NCT04310215 - Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

March 3, 2020

Primary Completion Date

June 13, 2022

Study Completion Date

June 13, 2022

Conditions

Chondral or Osteochondral Lesion of Talus

Interventions

BIOLOGICAL

CARTISTEM®

"\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1. Procedure: Microfracture~2. Biological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)"

PROCEDURE

Microfracture

"\*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠~1\. Procedure: Microfracture"

Trial Locations (6)

22332

Inha University Hospital, Incheon

35015

Chungnam National University Hospital, Daejeon

02447

Kyunghee University Medical Center, Seoul

06273

Gangnam Severance Hospital, Seoul

06351

Samsung Medical Center, Seoul

08308

Korea University Guro Hospital, Seoul

All Listed Sponsors

lead

Hyundai Bioland Co., Ltd.

INDUSTRY

collaborator

Medipost Co Ltd.

INDUSTRY